Security key
22663K107
Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX)
CUSIP: 22663K107
Q4 2020 13F Holders as of 31 Dec 2020
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 30,426,213
- Total 13F value
- $429,299,885
- Share change
- -282,663
- SEC-reported price per share
- $14.11
- Number of holders
- 84
- Value change
- -$4,592,533
- Number of buys
- 49
- Number of sells
- 20
- Shares outstanding
- 105,000,216
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2020
Institutions
84
Top holders
10
CRNX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2021
Previous quarter: Q3 2020
Crinetics Pharmaceuticals, Inc. SEC filings
Crinetics Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 22663K107
Recent filing periods:
Ownership snapshot
Top reported holders of CRNX - Crinetics Pharmaceuticals, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
30 Sep 2020
13F
Lead comparable stake: 4.7%
Showing 1-6 of 15 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 4.7%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
4.7%
PERCEPTIVE ADVISORS LLC
3.5%
ORBIMED ADVISORS LLC
2.6%
RA CAPITAL MANAGEMENT, L.P.
2.2%
Vivo Capital, LLC
2.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
Company
|
4.7%
|
$77,293,000
4,932,516 shares
|
— | 30 Sep 2020 |
| PERCEPTIVE ADVISORS LLC |
13F
Company
|
3.5%
|
$57,342,000
3,659,381 shares
|
— | 30 Sep 2020 |
| ORBIMED ADVISORS LLC |
13F
Company
|
2.6%
|
$43,148,000
2,753,567 shares
|
— | 30 Sep 2020 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
2.2%
|
$36,491,000
2,328,698 shares
|
— | 30 Sep 2020 |
| Vivo Capital, LLC |
13F
Company
|
2.2%
|
$35,473,000
2,263,770 shares
|
— | 30 Sep 2020 |
| Versant Venture Management, LLC |
13F
Company
|
1.9%
|
$31,820,000
2,030,616 shares
|
— | 30 Sep 2020 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2020
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
84
Shares
30,426,213
Rows available
84
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2020 vs Q3 2020 Across Filers
Q3 2020 holders
70
Q4 2020 holders
84
Holder diff
14
| Investor | Q3 2020 Shares | Q4 2020 Shares | Share Diff | Share Chg % | Q3 2020 value | Q4 2020 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend